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The relationship between the clotting cascade and the
promotion or inhibition of the anti-inflammatory response
continues to be defined through basic research. The
potential key role of proteins that were originally believed to
be exclusively involved in coagulation in the inflammatory
response provides an exciting potential mechanism(s) for
modification through the application of new therapies. The
accompanying review by Riewald and Ruf [1] outlines the
available information on the possible steps involving some of
the various proteins that are common to both coagulation
and inflammation. The complexity of the multiple actions of
the proteins in both inflammation and coagulation should
excite the clinician with regard to potential new therapies that
may be beneficial via activation of one or both of the
concurrent pathways [2]. However, before clinicians can
administer new therapies that utilize new knowledge on the
actions of coagulation cascade components, and hence
improve the outcomes of their patients, several gaps in our
current understanding must be addressed. This information is
imperative if the clinician is to take basic knowledge ‘to the
bedside’, where individual patients can benefit.
Optimum balance between pro-/anti-
coagulation and pro-/anti-inflammation
Administration of intrinsic or synthetic analogues of
coagulation cascade components (e.g. protein C, thrombin,
and factor VIIa or Xa), coagulation inhibitors (e.g. heparin or
analogues), or agonists or antagonists of the protease-
activated receptors, in an attempt to alter the individual
patient’s coagulation/inflammation balance, could
theoretically produce responses ranging from beneficial to
detrimental. Knowledge of the ‘most beneficial’ balance
between augmenting or inhibiting the contribution of the
clotting cascade components to inflammation would be
required for determining the selection and dosing of potential
new therapies.
Altering the intrinsic balance of coagulation
and inflammation: detrimental consequences
A safe assumption is that any new therapies that alter the
intrinsic response to coagulation and inflammatory stimulants
would also potentially produce detrimental effects on these,
and potentially other, physiological responses. A simple
example of such a potential for detrimental effects is the
administration of protein C resulting in undesirable
haemorrhage [3]. This example illustrates that a broader
knowledge of the impact of altering the coagulation/
inflammatory response will be required before clinicians can
comfortably utilize new therapies in patient care.
Patient variables that must be considered if
the balance is to be altered
All critically ill septic patients are not the same. It is unlikely
that any new therapies resulting from the new knowledge of
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Abstract
The relationship between blood coagulation factors and the promotion or inhibition of the anti-
inflammatory response continues to be defined through basic research. The potential key role of blood
coagulation factors in the response during sepsis provides an exciting potential mechanism(s) for
modification through the application of new therapies. The complexity of the potential multiple actions
of the proteins, such as protein C, should allow for development of new therapies to minimize the
detrimental inflammatory response. However, several gaps in our current understanding must be
bridged before the clinician can take the basic knowledge ‘to the bedside’, where individual patients
will benefit.
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the contribution of the clotting cascade to inflammation can
be applied to all patients. It can be anticipated that certain
patients would have contraindications to the new therapies or
that dosages would need to be adjusted on the basis of
pharmacokinetic or pharmacodynamic variables. The clinician
will need to know what these contraindications and variables
are before the new therapies can be used confidently. Some,
such as coagulation disorders, may be known and obvious,
but any new strategies that could potentially alter the balance
of a complex physiological response may be anticipated to
be influenced by many, as yet unknown, factors in the
individual patient. An example is the concurrent
administration of heparin, which appears to antagonize the
anti-inflammatory effect of antithrombin III in septic patients
[4]. A more complete understanding of the impact of
concurrent conditions, therapies and the patient’s genetic
make-up on outcome will be required if we are to obtain the
maximum benefit from new therapies.
Assessing individual intrinsic response at the
bedside
For any new therapy resulting from our expanded knowledge
of the clotting cascade in the inflammatory response to be
tailored to the needs of the individual patient, a method(s) for
rapidly and easily assessing the patient’s dynamic
inflammatory response will be required. Unless any new
therapies have very benign toxicities, the need to assess the
need, dosage and response to treatment will mandate
sensitive and specific monitoring techniques. Bedside or
clinical laboratory techniques that could be applicable to
most clinical environments would allow the benefit of any
new therapies to be applied to the greatest number of
patients. Conversely, any new treatments that require
complex, laborious monitoring techniques will have limited
applicability.
What agents have the ‘best’ activity in
altering the intrinsic
coagulation/inflammation balance?
As our knowledge of the contribution of the intrinsic
coagulation components increases, the development of many
potential new therapies will hopefully emerge for clinical use.
These may be totally new therapeutic entities or new
strategies for using existing drugs or clotting factors. Such
developments will create the new dilemma for the clinician,
namely that of trying to select between different treatment
options for the individual patient. Clinical trials outlining the
potential anticipated benefit(s) and the appropriate target
patient population for each new therapeutic strategy will
need to be completed. This will allow the clinician to ensure
that the most appropriate strategy can be selected for the
individual patient.
Conclusion
The above-mentioned concerns aside, the clinician should be
excited about the expanding knowledge of the role of
coagulation cascade components in modifying the
inflammatory response [5]. Such knowledge will hopefully
result in new strategies and therapies to manage the septic
patient. Previous knowledge and therapeutic attempts have
been disappointing [6].
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